Articles from ACTG

CHAPEL HILL, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IPACE-HIV study (Improving Physical Ability and Cellular Senescence Elimination in HIV), also known as A5426. IPACE-HIV is a phase 2, double-blind, randomized study evaluating the safety, tolerability, and efficacy of dasatinib and quercetin in improving physical function outcomes in people living with HIV who are frail or exhibit symptoms that they may become frail.

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced data finding that treating people living with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD) with semaglutide significantly improved a variety of biomarkers of cardiovascular risk. These results from the SLIM LIVER study (also known as A5371) will be shared as a poster presentation, “Semaglutide Improves Markers of Cardiovascular Risk in People with HIV: The SLIM LIVER Study” today, Monday, November 10, at 1:00 pm ET at the 2025 AASLD Liver Meeting, taking place in Washington D.C.

Presentations Address Frailty, Inflammation, Asymptomatic Heart Muscle Damage, and Mental Function

LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented promising findings from a study exploring how treating asymptomatic cytomegalovirus (CMV) in people living with HIV may improve immune function and physical health. The results from study A5383 were shared as the oral abstract, “Asymptomatic CMV Suppression with Letermovir Improves Immunologic and Functional Aging-related Outcomes in Treated HIV” at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California.

LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not improve mpox resolution. The results from STOMP (Study of Tecovirimat for Mpox, also known as A5418) were shared as the oral abstracts, “Tecovirimat is Safe but not Efficacious in People with Clade II Mpox” and “Host and Disease Factors Were Not Associated with the Resolution of Mpox in Participants Receiving Tecovirimat” at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California. STOMP stopped enrolling participants in December 2024 after an interim analysis showed that the treatment did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease.

Presentations highlight relationship between semaglutide and blood markers of gene modification age predictors, gut bacteria, heart and metabolic effects, and fat in the liver

LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased the risk of weight gain and cardiometabolic complications over the next five years compared to remaining on a regimen without an integrase inhibitor. They did not find an increased risk of major adverse cardiovascular events (MACE), such as heart attacks or strokes. These results from the REPRIEVE (The Randomized Trial to Prevent Vascular Events in HIV) study were shared as the late breaking poster presentation, “Risk of Obesity, Cardiometabolic Disease and MACE after Switch to an Integrase Inhibitor in REPRIEVE” at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California.

ACACIA Study Is Evaluating Two Long-Acting Broadly Neutralizing Antibodies Given at HIV Treatment Initiation

Data demonstrate superiority of HepB-CpG vaccination over conventional hepatitis B vaccines among people living with HIV

LOS ANGELES, Nov. 14, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced two oral presentations on tuberculosis (TB) therapy that took place at The Union Conference on Lung Health 2024, in Bali, Indonesia. The oral presentation “Six Months is a Lot of Time to Lie:” Disclosure and Treatment Preferences Among Participants in a Tuberculosis Therapeutic Trial was presented by Faith Mugodhi, M.Sc., H.S.W., University of Zimbabwe-Clinical Trials Research Centre (UZ-CTRC). The oral presentation High Prevalence of Fluoroquinolone Resistance and katG Mutations in Adult Index Patients in a Multinational MDR-TB Prevention Trial was presented by Soyeon Kim, Sc.D., IMPAACT Senior Statistician, Frontier Science Foundation.

Additional ACTG Presentations Address Muscle Density and Area among People Living with HIV and COVID-19 Treatment

PAUSE Study Is Evaluating two Long-Acting Broadly Neutralizing Antibodies

LOS ANGELES, May 10, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the publication of results from SLIM LIVER (also known as A5371) in the Annals of Internal Medicine. “The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV” demonstrates that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV.

Study will enroll participants who initiated treatment shortly after acquiring HIV

LOS ANGELES, March 06, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today made the oral presentation “HepB-CpG Vaccine is Superior to HepB-alum in People with HIV and Prior Vaccine Non-Response (A5379)” at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver, Colorado. These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.

LOS ANGELES, March 06, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented the oral abstract “Long-Acting Injectable CAB/RPV is Superior to Oral ART in PWH with Adherence Challenges: ACTG A5359” at the Conference on Retroviruses and Opportunistic Infections (CROI 2024), in Denver, Colorado. Today’s presentation includes the first data to demonstrate that long-acting cabotegravir and rilpivirine administered every four weeks had superior efficacy to daily oral antiretroviral treatment (ART) among people living with HIV who had previously been unable to maintain viral suppression while taking an oral daily regimen.

LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced an oral presentation from its SLIM LIVER study (also known as A5371), “Semaglutide Reduces Metabolic-Associated Steatotic Liver Disease in People with HIV: the SLIM LIVER Study” at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver, Colorado. Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented. Together, these presentations demonstrate that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV. They also demonstrate that while muscle volume decreased with semaglutide-induced weight loss, no significant changes in physical function were observed.

LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented the poster “Suppressing Asymptomatic CMV with Letermovir Reshapes Cardiometabolic Proteome in Treated HIV” at the Conference on Retroviruses and Opportunistic Infections (CROI 2024), in Denver, Colorado. Today’s presentation from study A5383 is the first to demonstrate that a specific inhibitor of cytomegalovirus (CMV) is safe and broadly impacts immunologic and cardiometabolic biomarkers in people living with HIV, which may explain the association between CMV and aging-related HIV co-morbidities.

LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5406 (Pharmacokinetics and Safety of Double-dose Dolutegravir When Used with Rifapentine for HIV-associated Tuberculosis). A5406 is a phase 2, open-label pharmacokinetic study investigating the effect that the anti-tuberculosis (TB) medication rifapentine has on levels of the HIV medication dolutegravir in the blood of participants who have HIV-associated TB and whether this combination can be safely and effectively used together.

Regimen Would Decrease Duration of Treatment from Nine to Six Months